Literature DB >> 20687529

Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Galina Tsurupa1, Sergiy Yakovlev, Patrick McKee, Leonid Medved.   

Abstract

Covalent incorporation (cross-linking) of plasmin inhibitor alpha(2)-antiplasmin (alpha(2)-AP) into fibrin clots increases their resistance to fibrinolysis. We hypothesized that alpha(2)-AP may also interact noncovalently with fibrin prior to its covalent cross-linking. To test this hypothesis, we studied binding of alpha(2)-AP to fibrin(ogen) and its fragments by an enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance. The experiments revealed that alpha(2)-AP binds to polymeric fibrin and surface-adsorbed fibrin(ogen), while no binding was observed with fibrinogen in solution. To localize the alpha(2)-AP-binding sites, we studied the interaction of alpha(2)-AP with the fibrin(ogen)-derived D(1), D-D, and E(3) fragments, and the recombinant alphaC region and its constituents, alphaC connector and alphaC domain and its subdomains, which together encompass practically the whole fibrin(ogen) molecule. In the ELISA, alpha(2)-AP bound to immobilized D(1), D-D, alphaC region, alphaC domain, and its C-terminal subdomain. The binding was Lys-independent and was not inhibited by plasminogen or tPA. Furthermore, the affinity of alpha(2)-AP for D-D was significantly increased in the presence of plasminogen, while that to the alphaC domain remained unaffected. Altogether, these results indicate that the fibrin(ogen) D region and the C-terminal subdomain of the alphaC domain contain high-affinity alpha(2)-AP-binding sites that are cryptic in fibrinogen and exposed in fibrin or adsorbed fibrinogen, and the presence of plasminogen facilitates interaction of alpha(2)-AP with the D regions. The discovered noncovalent interaction of alpha(2)-AP with fibrin may contribute to regulation of the initial stage of fibrinolysis and provide proper orientation of the cross-linking sites to facilitate covalent cross-linking of alpha(2)-AP to the fibrin clot.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687529      PMCID: PMC2932838          DOI: 10.1021/bi1010317

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  46 in total

1.  On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin.

Authors:  B Wiman; D Collen
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

2.  Structure of the carboxyl-terminal half of human alpha 2-plasmin inhibitor deduced from that of cDNA.

Authors:  Y Sumi; Y Nakamura; N Aoki; M Sakai; M Muramatsu
Journal:  J Biochem       Date:  1986-11       Impact factor: 3.387

3.  The effect of plasmin on the subunit structure of human fibrinogen.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1972-02-10       Impact factor: 5.157

4.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

5.  Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor.

Authors:  T Sasaki; T Morita; S Iwanaga
Journal:  J Biochem       Date:  1986-06       Impact factor: 3.387

6.  On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.

Authors:  B Wiman; H R Lijnen; D Collen
Journal:  Biochim Biophys Acta       Date:  1979-07-25

7.  Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency.

Authors:  N Aoki; H Saito; T Kamiya; K Koie; Y Sakata; M Kobakura
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

9.  Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.

Authors:  S Kimura; N Aoki
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more
  17 in total

1.  The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.

Authors:  Masayoshi Souri; Tsukasa Osaki; Akitada Ichinose
Journal:  J Biol Chem       Date:  2015-03-25       Impact factor: 5.157

2.  The assembly of nonadhesive fibrinogen matrices depends on the αC regions of the fibrinogen molecule.

Authors:  Ivan S Yermolenko; Oleg V Gorkun; Alexander Fuhrmann; Nataly P Podolnikova; Valeryi K Lishko; Stanislav P Oshkadyerov; Susan T Lord; Robert Ros; Tatiana P Ugarova
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

3.  On the mechanism of αC polymer formation in fibrin.

Authors:  Galina Tsurupa; Igor Pechik; Rustem I Litvinov; Roy R Hantgan; Nico Tjandra; John W Weisel; Leonid Medved
Journal:  Biochemistry       Date:  2012-03-15       Impact factor: 3.162

4.  Structure, stability, and interaction of fibrin αC-domain polymers.

Authors:  Galina Tsurupa; Ariza Mahid; Yuri Veklich; John W Weisel; Leonid Medved
Journal:  Biochemistry       Date:  2011-08-24       Impact factor: 3.162

Review 5.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

6.  Biochemical and structural analysis of the interaction between β-amyloid and fibrinogen.

Authors:  Daria Zamolodchikov; Hanna E Berk-Rauch; Deena A Oren; Daniel S Stor; Pradeep K Singh; Masanori Kawasaki; Kazuyoshi Aso; Sidney Strickland; Hyung Jin Ahn
Journal:  Blood       Date:  2016-07-07       Impact factor: 22.113

7.  Evaluating the Effects of Fibrinogen αC Mutations on the Ability of Factor XIII to Crosslink the Reactive αC Glutamines (Q237, Q328, Q366).

Authors:  Kelly Njine Mouapi; Lucille J Wagner; Chad A Stephens; Mohammed M Hindi; Daniel W Wilkey; Michael L Merchant; Muriel C Maurer
Journal:  Thromb Haemost       Date:  2019-05-05       Impact factor: 5.249

8.  Purification and characterization of tenerplasminin-1, a serine peptidase inhibitor with antiplasmin activity from the coral snake (Micrurus tener tener) venom.

Authors:  Jeilyn Vivas; Carlos Ibarra; Ana M Salazar; Ana G C Neves-Ferreira; Elda E Sánchez; Jonás Perales; Alexis Rodríguez-Acosta; Belsy Guerrero
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2015-09-28       Impact factor: 3.228

9.  A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.

Authors:  K Hess; S H Alzahrani; M Mathai; V Schroeder; A M Carter; G Howell; T Koko; M W J Strachan; J F Price; K A Smith; P J Grant; R A Ajjan
Journal:  Diabetologia       Date:  2011-09-15       Impact factor: 10.122

Review 10.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.